Mat Kladney, MD

I am the site PI for two collaborative NIH/NIDA funded clinical trials exploring how best to care for patients with opioid use disorder (OUD).  

1.) CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy

2.) GLP-1R Agonist Treatment for Opioid Use Disorder

The first phase of the CTN-0100 trial, "Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy", is trying to discover what doses and forms of buprenorphine work best for people with untreated opioid use disorder (OUD) and if a motivational smartphone app is effective in treating this population.  The second phase of the CTN-0100 trial is trying to determine which pharmacological strategies work best for people who are stably treated with buprenorphine or naltrexone for OUD and are trying to lower their medication dose or stop it entirely.

The multisite placebo controlled trial "GLP-1R Agonist Treatment for Opioid Use Disorder" is trying to discover if adding a GLP-1 agonist (semaglutide) to the standard of care for opioid use disorder (methadone or buprenorphine) will improve outcomes in people who are continuing to use opioids despite usual treatment.

Additionally, I am the PI for DC-BUPE a NIH/NIDA funded study examining the experience of people who have attempted to stop buprenorphine for treatment of OUD.  This qualitative research study is trying to determine why some people are able to stop buprenorphine for treatment of OUD while others are not, and identify risk factors for return to non-prescribed opioid use when someone is tapering off buprenorphine.

Aside from substance use disorder research I am also responsible for many educational initiatives for medical students, residents, and faculty related to substance use disorders.  I have taken my addiction teaching sessions to several national conferences, statewide educational initiatives, as well as for residency programs outside of New York City.